- Home
- ADV vs DNA Comparison
ADV vs DNA Comparison
Compare ADV & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADV
- DNA
- Stock Information
- Founded
- ADV 1987
- DNA 2008
- Country
- ADV United States
- DNA United States
- Employees
- ADV N/A
- DNA N/A
- Industry
- ADV Business Services
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADV Consumer Discretionary
- DNA Health Care
- Exchange
- ADV Nasdaq
- DNA Nasdaq
- Market Cap
- ADV 420.4M
- DNA 466.4M
- IPO Year
- ADV N/A
- DNA N/A
- Fundamental
- Price
- ADV $1.47
- DNA $7.76
- Analyst Decision
- ADV Strong Buy
- DNA Sell
- Analyst Count
- ADV 1
- DNA 5
- Target Price
- ADV $3.50
- DNA $17.25
- AVG Volume (30 Days)
- ADV 360.6K
- DNA 1.2M
- Earning Date
- ADV 05-12-2025
- DNA 05-06-2025
- Dividend Yield
- ADV N/A
- DNA N/A
- EPS Growth
- ADV N/A
- DNA N/A
- EPS
- ADV N/A
- DNA N/A
- Revenue
- ADV $3,566,324,000.00
- DNA $237,417,000.00
- Revenue This Year
- ADV N/A
- DNA N/A
- Revenue Next Year
- ADV N/A
- DNA $16.74
- P/E Ratio
- ADV N/A
- DNA N/A
- Revenue Growth
- ADV N/A
- DNA 13.76
- 52 Week Low
- ADV $1.11
- DNA $5.00
- 52 Week High
- ADV $4.68
- DNA $38.60
- Technical
- Relative Strength Index (RSI)
- ADV 55.91
- DNA 53.73
- Support Level
- ADV $1.27
- DNA $6.42
- Resistance Level
- ADV $1.41
- DNA $8.18
- Average True Range (ATR)
- ADV 0.08
- DNA 0.62
- MACD
- ADV 0.04
- DNA 0.04
- Stochastic Oscillator
- ADV 96.36
- DNA 65.37
About ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.